These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Efficacy of a long-term secondary prevention programme following inpatient cardiovascular rehabilitation on risk and health-related quality of life in a low-education cohort: a randomized controlled study. Mayer-Berger W; Simic D; Mahmoodzad J; Burtscher R; Kohlmeyer M; Schwitalla B; Redaèlli M Eur J Prev Cardiol; 2014 Feb; 21(2):145-52. PubMed ID: 23111536 [TBL] [Abstract][Full Text] [Related]
28. Cardiac rehabilitation in New Zealand-moving forward. Benatar J; Langdana F; Doolan-Noble F; McLachlan A N Z Med J; 2016 May; 129(1435):68-74. PubMed ID: 27355170 [TBL] [Abstract][Full Text] [Related]
29. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262 [TBL] [Abstract][Full Text] [Related]
30. [Complex cardiac rehabilitation in a strategy of secondary prevention of cardiovascular disease]. Kałka D; Sobieszczańska M; Pilecki W; Adamus J Pol Merkur Lekarski; 2009 Jul; 27(157):30-5. PubMed ID: 19650426 [TBL] [Abstract][Full Text] [Related]
31. Secondary prevention of stroke. Birns J; Bhalla A Br J Hosp Med (Lond); 2015 Jul; 76(7):C104-7. PubMed ID: 26140570 [No Abstract] [Full Text] [Related]
32. The role of cardiac rehabilitation in secondary prevention after coronary events. Peersen K; Munkhaugen J; Gullestad L; Liodden T; Moum T; Dammen T; Perk J; Otterstad JE Eur J Prev Cardiol; 2017 Sep; 24(13):1360-1368. PubMed ID: 28664773 [TBL] [Abstract][Full Text] [Related]
33. Exercise and its role in the prevention and rehabilitation of cardiovascular disease. Miller TD; Balady GJ; Fletcher GF Ann Behav Med; 1997; 19(3):220-9. PubMed ID: 9603697 [TBL] [Abstract][Full Text] [Related]
34. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003 [TBL] [Abstract][Full Text] [Related]
35. Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736 [TBL] [Abstract][Full Text] [Related]
36. Role of antiplatelet drugs in the prevention of cardiovascular events. Tendera M; Wojakowski W Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562 [TBL] [Abstract][Full Text] [Related]
37. Attending Heart School and long-term outcome after myocardial infarction: A decennial SWEDEHEART registry study. Wallert J; Olsson EM; Pingel R; Norlund F; Leosdottir M; Burell G; Held C Eur J Prev Cardiol; 2020 Jan; 27(2):145-154. PubMed ID: 31514507 [TBL] [Abstract][Full Text] [Related]
38. Secondary prevention of cardiovascular diseases: current state of the art. Hasenfuß G Kardiol Pol; 2018; 76(12):1671-1679. PubMed ID: 30338502 [TBL] [Abstract][Full Text] [Related]
39. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114 [TBL] [Abstract][Full Text] [Related]
40. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review. Khalil P; Kabbach G Curr Cardiol Rep; 2019 Jan; 21(1):5. PubMed ID: 30689068 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]